ALK and non-small cell lung carcinoma: A recent open‐label, phase 3 trial suggested that first‐line crizotinib was superior to standard pemetrexed plus platinum chemotherapy in patients with previously untreated, advanced, ALK‐positive non‐squamous NSCLC 14.